NCT04393935Completed
Pharmacy-based Pre-exposure Prophylaxis
Advancing Pre-exposure Prophylaxis (PrEP) Access in Pharmacies to Improve PrEP Uptake in Disadvantaged Areas
Source: ClinicalTrials.gov · Last updated 28 May 2025
Brief summary (registry, in English)
The proposed research will develop a culturally appropriate pharmacy pre-exposure prophylaxis (PrEP) delivery model for black men who have sex with men (BMSM) who live in high poverty, racial minority neighborhoods. Increasing access to PrEP through pharmacies has the potential to increase PrEP uptake among BMSM thereby reducing HIV incidence and racial inequities in HIV.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 49 (actual)
- First submitted
- 15 May 2020
- Start date
- 19 May 2022
- Primary completion date
- 11 May 2024
- Lead sponsor
- Emory University
- Diseases
- HIV
- NCT number
- NCT04393935
What you commit to
- Study type: Interventional
- Participants enrolled: 49
- From 19 May 2022 to the primary completion date, 11 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- Consent to participate in the online screener
- Can speak and read English without any help
- Test negative for HIV
- Agree to receive medication from the pharmacy
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.